Biofil Chemicals & Pharmaceuticals Limited announced its 41st Annual General Meeting (AGM) is scheduled for September 23, 2026, at 3:00 pm. The meeting will be conducted via Video Conferencing or Other Audio Visual Means (VC/OAVM). The notice was issued on August 26, 2026, pursuant to Regulation 30 read with Schedule III Part A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Agenda Items

The AGM will transact both ordinary and special business. Ordinary business includes the adoption of audited financial statements for FY26 and the re-appointment of Mr. Smitesh Shah as a Non-Executive Non-Independent Director. He retires by rotation under Section 152(6) of the Companies Act, 2013.

Special business includes two critical resolutions:

• Continuation of Independent Director: Shareholders are asked to approve a special resolution for the continuation of Mr. Ashok Kumar Ramawat’s directorship as a Non-Executive Independent Director upon attaining the age of 75 years on September 27, 2027, in compliance with Regulation 17(1A) of SEBI Listing Regulations.
• Related Party Transactions (RPT): An ordinary resolution seeks approval for material related party transactions with Cyano Pharma Private Limited (CPPL) for an aggregate value of up to ₹20 crore during FY27 and until the 42nd AGM.

Related Party Transaction Details

The proposed transactions with CPPL involve the purchase and sale of goods, job work services, and other resource transfers in the ordinary course of business. The Audit Committee approved the proposal, noting that the aggregate value exceeds the materiality threshold of 10% of the company’s annual consolidated turnover for FY26.

Mr. Ketan Shah (Chairman & Managing Director) and Mr. Smitesh Shah are shareholders in CPPL, establishing the related party relationship under Section 2(76) of the Companies Act, 2013. The transactions are expected to leverage CPPL’s supply network to optimize marketing and distribution costs.

Voting and Participation Details

Members can participate via VC/OAVM using the CDSL electronic platform. Remote e-voting is facilitated for all resolutions. The cut-off date for voting rights is September 16, 2026. The remote e-voting period runs from September 20, 2026, at 9:00 am to September 22, 2026, at 5:00 pm.

The Board approved the notice of the AGM on August 11, 2026. Ms. Darshika Wankhede, a Practicing Company Secretary, has been appointed as the Scrutinizer for the meeting. Results of the resolutions will be announced within two working days of the conclusion of the AGM.

Physical copies of the annual report are not being dispatched. Electronic copies have been sent to registered email addresses, while web-link letters are being sent to those without registered emails. Members holding shares in physical form are advised to update their KYC details with the Registrar and Share Transfer Agent, Ankit Consultancy Private Limited.

Regulatory Compliance

The meeting adheres to the Companies Act, 2013, and relevant circulars from the Ministry of Corporate Affairs (MCA) and SEBI. Apoorv Jain, Company Secretary and Compliance Officer, signed the disclosure dated August 11, 2026. The company reminded shareholders of the SEBI circular allowing the transfer and dematerialization of physical securities lodged before April 1, 2019, within the specified window ending February 4, 2027.

biofil chemicals reported a sharp divergence in its first-quarter FY27 financial results, with revenue surging 92% year-on-year to ₹1,235.02 lakh while net profit plummeted 95% to ₹10.91 lakh. The Board of Directors approved the unaudited standalone results on August 11, 2026, citing increased trading activities in the Chemical Division as the primary driver for top-line growth. Despite the robust revenue expansion, profitability contracted significantly as the Pharma Division posted a segment loss and 'Other Income' collapsed from ₹283.20 lakh in Q1FY26 to just ₹6.26 lakh. The company also disclosed that its manufacturing facility is undergoing renovation to comply with revised Schedule M regulations, with completion expected within three to six months.

The Board meeting held on August 11, 2026, addressed key governance matters alongside the financial approvals. Ashok Kumar Ramawat was continued as a Non-Executive Independent Director upon attaining the age of 75 years, based on recommendations from the Nomination and Remuneration Committee. The Board also approved the Board’s Report on Operations and the Corporate Governance Report for the year ended March 31, 2026. Additionally, the company scheduled its 41st Annual General Meeting for September 23, 2026, to be conducted via Video Conferencing or Other Audio-Visual Means (OAVM). In compliance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published the results in newspapers including Free Press Mumbai & Indore and Choutha Sansar on August 12, 2026.

Financial Performance

Revenue from operations climbed to ₹1,235.02 lakh in Q1FY27, compared to ₹643.26 lakh in the corresponding quarter of the previous year. Total income stood at ₹1,241.28 lakh, up from ₹926.46 lakh in Q1FY26. However, this increase was largely offset by a drastic fall in other income, which dropped to ₹6.26 lakh from ₹283.20 lakh in the prior year period. Total expenses increased to ₹1,227.87 lakh from ₹650.21 lakh, primarily due to higher purchases of stock-in-trade and cost of materials consumed associated with expanded trading volumes. Consequently, Profit Before Tax fell to ₹13.41 lakh from ₹276.25 lakh, and Net Profit after tax declined to ₹10.91 lakh from ₹241.10 lakh.

Segment Analysis

The Chemical Division was the primary driver of revenue growth, contributing ₹921.62 lakh compared to ₹158.51 lakh in Q1FY26. This division generated a segment profit of ₹15.43 lakh. In contrast, the Pharma Division saw revenue decline to ₹313.40 lakh from ₹484.75 lakh and incurred a segment loss of ₹6.41 lakh, widening from a profit of ₹269.74 lakh in the previous year. This divergence highlights a strategic shift towards trading activities rather than manufactured pharma products during this quarter. Earnings Per Share (EPS) for the quarter stood at ₹0.07 (Basic and Diluted), down significantly from ₹1.48 in Q1FY26.

What the Numbers Show

The financial data reveals a structural shift in Biofil Chemicals’ operations during Q1FY27. While revenue nearly doubled, the nature of this growth is predominantly transactional, evidenced by the sharp rise in 'Purchases of stock-in-trade' and 'Cost of materials consumed'. The collapse in 'Other Income' from ₹283.20 lakh to ₹6.26 lakh suggests that the prior year’s profitability was partly supported by non-operational gains, which are no longer present. Furthermore, the Pharma Division’s transition from a high-margin profit center to a loss-making unit indicates ongoing operational challenges or strategic pausing, likely linked to the mentioned manufacturing facility upgrades. Investors should monitor whether the upcoming completion of Schedule M compliance will restore manufacturing-led margins in subsequent quarters. SEBI has also provided a special one-year window, from February 05, 2026, to February 04, 2027, for investors to re-lodge old physical share transfer deeds submitted before April 1, 2019, if they were rejected or not processed due to deficiencies.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE829A01014/0c4a4c87-ef98-49c5-ae4b-b80585a3f257.pdf